6.47
price down icon0.31%   -0.02
after-market After Hours: 6.47
loading
Trevi Therapeutics Inc stock is traded at $6.47, with a volume of 999.57K. It is down -0.31% in the last 24 hours and up +6.59% over the past month. Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
See More
Previous Close:
$6.49
Open:
$6.56
24h Volume:
999.57K
Relative Volume:
0.44
Market Cap:
$658.32M
Revenue:
-
Net Income/Loss:
$-29.07M
P/E Ratio:
-22.31
EPS:
-0.29
Net Cash Flow:
$-31.85M
1W Performance:
+0.23%
1M Performance:
+6.59%
6M Performance:
+133.57%
1Y Performance:
+128.62%
1-Day Range:
Value
$6.43
$6.64
1-Week Range:
Value
$6.115
$6.78
52-Week Range:
Value
$2.30
$7.39

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name
Name
Trevi Therapeutics Inc
Name
Phone
203-304-2499
Name
Address
195 CHURCH STREET, NEW HAVEN, CT
Name
Employee
31
Name
Twitter
@TreviThera
Name
Next Earnings Date
2025-03-18
Name
Latest SEC Filings
Name
TRVI's Discussions on Twitter

Compare TRVI with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TRVI
Trevi Therapeutics Inc
6.47 656.76M 0 -29.07M -31.85M -0.29
Biotechnology icon
ONC
Beigene Ltd Adr
236.86 24.29B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
447.18 110.94B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.2996 45.05M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
614.79 61.99B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
74.73 5.75B 0 -153.72M -103.81M -2.00

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-10-25 Reiterated Needham Buy
Mar-10-25 Upgrade Raymond James Outperform → Strong Buy
Dec-12-24 Reiterated H.C. Wainwright Buy
Sep-09-24 Resumed Leerink Partners Outperform
Aug-30-24 Initiated H.C. Wainwright Buy
Aug-30-24 Initiated Raymond James Outperform
Jun-13-24 Initiated Rodman & Renshaw Buy
Apr-12-23 Initiated B. Riley Securities Buy
Nov-22-22 Initiated SVB Leerink Outperform
Jun-03-19 Initiated BMO Capital Markets Outperform
Jun-03-19 Initiated Needham Buy
Jun-03-19 Initiated SVB Leerink Outperform
Jun-03-19 Initiated Stifel Buy
View All

Trevi Therapeutics Inc Stock (TRVI) Latest News

pulisher
09:35 AM

Trevi Therapeutics (TRVI): Analyst Reiterates Buy Rating with $2 - GuruFocus

09:35 AM
pulisher
08:05 AM

Trevi Therapeutics, Inc. Announces Additional Analyses from Phase 2A River Trial of Haduvio in Patients with Refractory Chronic Cough - marketscreener.com

08:05 AM
pulisher
07:47 AM

Trevi Therapeutics (TRVI) Reveals New Findings from Phase 2a RIV - GuruFocus

07:47 AM
pulisher
07:20 AM

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough | TRVI Stock News - GuruFocus

07:20 AM
pulisher
07:17 AM

Raymond James sets $29 target for Trevi Therapeutics stock By Investing.com - Investing.com Nigeria

07:17 AM
pulisher
07:11 AM

Trevi Therapeutics Announces Additional Analyses From Phase 2A River Trial Of Haduvio In Patients With Refractory Chronic Cough - marketscreener.com

07:11 AM
pulisher
07:00 AM

Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough - PR Newswire

07:00 AM
pulisher
May 19, 2025

Prurigo Nodularis Market on Track for Major Expansion by 2034, According to DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail

May 19, 2025
pulisher
May 19, 2025

Price T Rowe Associates Inc. MD Has $104,000 Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 19, 2025
pulisher
May 17, 2025

Dimensional Fund Advisors LP Grows Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 17, 2025
pulisher
May 15, 2025

12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Raymond James Financial Inc. - Defense World

May 15, 2025
pulisher
May 14, 2025

Wall Street Analysts See a 195.05% Upside in Trevi Therapeutics (TRVI): Can the Stock Really Move This High? - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2025 Earnings Call Transcript - Insider Monkey

May 13, 2025
pulisher
May 11, 2025

Wells Fargo & Company MN Buys 9,562 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 11, 2025
pulisher
May 11, 2025

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha

May 11, 2025
pulisher
May 09, 2025

Trevi Therapeutics Reports Q1 2025 Results and Updates - TipRanks

May 09, 2025
pulisher
May 09, 2025

MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 09, 2025
pulisher
May 09, 2025

Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance

May 09, 2025
pulisher
May 08, 2025

Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations By Investing.com - Investing.com UK

May 08, 2025
pulisher
May 08, 2025

Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations - Investing.com

May 08, 2025
pulisher
May 08, 2025

Trevi Therapeutics (TRVI): Promising Data and Strategic Advances - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Trevi Therapeutics (TRVI): Promising Data and Strategic Advances | TRVI Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings: EPS of -$0.09 Beats Estimate, Reports $10.3 Million Net Loss - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | TRVI Stock News - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan

May 08, 2025
pulisher
May 08, 2025

Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 08, 2025
pulisher
May 08, 2025

Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX

May 08, 2025
pulisher
May 07, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 07, 2025
pulisher
May 06, 2025

Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

May 06, 2025
pulisher
May 06, 2025

Invesco Ltd. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 06, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Acquires 29,700 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 05, 2025
pulisher
May 04, 2025

Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - Defense World

May 04, 2025
pulisher
May 02, 2025

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 - StreetInsider

May 02, 2025
pulisher
May 01, 2025

Trevi Therapeutics to Report First Quarter 2025 Financial Result - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Trevi Therapeutics Inc [TRVI] Records 50-Day SMA of $5.77 - knoxdaily.com

May 01, 2025
pulisher
May 01, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

May 01, 2025
pulisher
Apr 29, 2025

A look at TRVI’s current quarter earnings estimates - uspostnews.com

Apr 29, 2025
pulisher
Apr 29, 2025

TRVI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com

Apr 29, 2025
pulisher
Apr 29, 2025

Quarterly Metrics: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX

Apr 29, 2025
pulisher
Apr 29, 2025

SEC Form DEF 14A filed by Trevi Therapeutics Inc. - Quantisnow

Apr 29, 2025
pulisher
Apr 29, 2025

JPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 29, 2025
pulisher
Apr 28, 2025

Recent Insider Activity Suggests Potential Gains for Trevi Therapeutics Inc (TRVI) - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

What is Trevi Therapeutics Inc (TRVI) Stock Return on Shareholders’ Capital? - Sete News

Apr 28, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 26, 2025

Geode Capital Management LLC Has $5.35 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 26, 2025
pulisher
Apr 24, 2025

Quarterly Snapshot: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX

Apr 24, 2025
pulisher
Apr 24, 2025

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI) - The Globe and Mail

Apr 24, 2025
pulisher
Apr 24, 2025

Trevi Therapeutics Inc (TRVI)’s results reveal risk - uspostnews.com

Apr 24, 2025
pulisher
Apr 23, 2025

Stifel maintains Trevi Therapeutics stock Buy rating, $15 target By Investing.com - Investing.com Canada

Apr 23, 2025
pulisher
Apr 14, 2025

12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Raymond James Financial Inc. - Defense World

Apr 14, 2025
pulisher
Apr 14, 2025

American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 14, 2025

Trevi Therapeutics Inc Stock (TRVI) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.32
price up icon 2.33%
$578.31
price up icon 0.04%
$32.63
price down icon 1.09%
$291.68
price down icon 0.06%
$4.20
price up icon 3.62%
$74.73
price up icon 2.96%
Cap:     |  Volume (24h):